Work

Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Figure 1. Average and standard deviation concentration–time profile of cabozantinib at steady-state on a semi-log plot for stratum A (A), stratum B (B), and stratum C (C). Doses are noted in the figures.

DOI: 10.1158/1078-0432.30902937

Authors: Missak Haigentz, Jeannette Y. Lee, Elizabeth Y. Chiao, David M. Aboulafia, Lee Ratner, Richard F. Ambinder, Robert A. Baiocchi, Ronald T. Mitsuyasu, William Wachsman, Joseph A. Sparano, Michelle A. Rudek

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4417428882

Cites:

Cited by:

Related to: